Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 1 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  3. US 12385013

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  4. US 12384790

    Pteridinone compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  5. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  6. US 12377252

    Implantation devices, system, and methods

    Vertex Pharmaceuticals Incorporated · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  8. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  9. US 12331057

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  10. US 12331334

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  11. US 12324802

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  12. US 12319693

    Crystalline forms of CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  13. US 12304900

    Islet cell manufacturing compositions and methods of use

    Vertex Pharmaceuticals Incorporated · Granted May 20, 2025 · Expires May 15, 2045

    granted
  14. US 12281057

    Carboxamides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  15. US 12269831

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  16. US 12258333

    N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  17. US 12251387

    Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  18. US 12247021

    Substituted tetrahydrofurans as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  19. US 12215355

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  20. US 12214083

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  21. US 12195453

    Antiproliferation compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  22. US 12194138

    Devices and methods for delivering therapeutics

    Vertex Pharmaceuticals Incorporated · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  23. US 12186306

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  24. US 12187731

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted